<?xml version="1.0" encoding="UTF-8"?>
<list>
  <sentences>
    <s path="[OANC]/data/written_2/technical/biomed/1471-2369-4-5.anc" start="15587" end="15593" sStart="15365" offset="222" sid="r11.severe.j.0355" wn="1" wnkey="severe%5:00:00:intense:00" text="In comparison to patients with other causes of ESRD, the patients with HIVAN included in the DMMS wave 2 study were younger, the majority were African-Americans and had lower serum albumin and more severe acidosis." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2369-4-5.anc" start="2655" end="2659" sStart="null" offset="56" sid="r7.poor.j.0894" wn="5" wnkey="poor%5:00:00:insufficient:00" text="Better understanding of factors associated with poor outcomes in patients with HIVAN and ESRD would help in improving outcomes in these patients." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2369-4-5.anc" start="12922" end="12926" sStart="null" offset="39" sid="r9.late.j.0912" wn="1" wnkey="late%3:00:00::" text="[ 19 20 ] HIVAN is generally a late manifestation of HIV infection." />
    <s path="file:/c:/OANC/data/written_2/technical/biomed/1471-2369-4-5.anc" start="16543" end="16547" sStart="null" offset="0" sid="null" wn="1" wnkey="know%2:31:01::" text="We did not &lt;b&gt;know&lt;/b&gt; the duration of use of medications prior to the study start." />
    <s path="file:/c:/OANC/data/written_2/technical/biomed/1471-2369-4-5.anc" start="16543" end="16547" sStart="null" offset="0" sid="null" wn="1" wnkey="know%2:31:01::" text="We did not &lt;b&gt;know&lt;/b&gt; the duration of use of medications prior to the study start." />
    <s path="file:/c:/OANC/data/written_2/technical/biomed/1471-2369-4-5.anc" start="16543" end="16547" sStart="null" offset="0" sid="null" wn="1" wnkey="know%2:31:01::" text="We did not &lt;b&gt;know&lt;/b&gt; the duration of use of medications prior to the study start." />
    <s path="file:/c:/OANC/data/written_2/technical/biomed/1471-2369-4-5.anc" start="16543" end="16547" sStart="null" offset="0" sid="null" wn="1" wnkey="know%2:31:01::" text="We did not &lt;b&gt;know&lt;/b&gt; the duration of use of medications prior to the study start." />
    <s path="file:/c:/OANC/data/written_2/technical/biomed/1471-2369-4-5.anc" start="16543" end="16547" sStart="null" offset="0" sid="null" wn="1" wnkey="know%2:31:01::" text="We did not &lt;b&gt;know&lt;/b&gt; the duration of use of medications prior to the study start." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2369-4-5.anc" start="7147" end="7152" sStart="null" offset="0" sid="null" wn="1" wnkey="date%1:28:00::" text="Of these, 3621 patients had valid &lt;b&gt;dates&lt;/b&gt; for starting dialysis in 1996." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2369-4-5.anc" start="9015" end="9026" sStart="null" offset="65" sid="r11.combination.n.0706" wn="1" wnkey="combination%1:14:00::" text="Five patients received both zidovudine and lamivudine (a combination later called Combivir TM)." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2369-4-5.anc" start="9060" end="9072" sStart="null" offset="6" sid="r11.combination.n.0166" wn="1" wnkey="combination%1:14:00::" text="Other combinations included one each for zidovudine-zalcitabine, stavudine-saquinavir, stavidine-lamivudine, and indinavir-lamivudine." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2369-4-5.anc" start="8906" end="8917" sStart="null" offset="123" sid="r11.combination.n.0378" wn="7" wnkey="combination%1:04:00::" text="Only 22 (61%) of patients with HIVAN received antiretroviral agents, and only nine patients (25%) received combination antiretroviral therapy." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2369-4-5.anc" start="6946" end="6952" sStart="null" offset="0" sid="null" wn="" wnkey="null" text="5 being equivalent to &lt;b&gt;chance&lt;/b&gt; and 1.0 equivalent to 100% agreement)." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2369-4-5.anc" start="6946" end="6952" sStart="null" offset="0" sid="null" wn="2" wnkey="chance%1:19:00::" text="5 being equivalent to &lt;b&gt;chance&lt;/b&gt; and 1.0 equivalent to 100% agreement)." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2369-4-5.anc" start="6946" end="6952" sStart="null" offset="0" sid="null" wn="" wnkey="null" text="5 being equivalent to &lt;b&gt;chance&lt;/b&gt; and 1.0 equivalent to 100% agreement)." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2369-4-5.anc" start="2967" end="2974" sStart="null" offset="198" sid="r11.benefit.n.0889" wn="2" wnkey="benefit%1:07:00::" text="More detailed information on the metabolic, cardiovascular and chronic kidney disease specific characteristics of HIVAN patients on dialysis, as well as the use and possible benefit of certain medications, especially ACE and antiretroviral drugs in this population, would supplement previous reports." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2369-4-5.anc" start="1864" end="1871" sStart="null" offset="63" sid="r11.benefit.n.0574" wn="2" wnkey="benefit%1:07:00::" text="[ 13 ] Although a recent single-center report found no benefit of ACE in dialysis patients with HIVAN [ 14 ] , it is not clear whether this represents national experience." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2369-4-5.anc" start="14841" end="14849" sStart="null" offset="103" sid="r11.benefit.n.0154" wn="2" wnkey="benefit%1:07:00::" text="Although a benefit of ACE use in HIV infected patients has been reported previously, [ 9 ] the benefits of ACE in retarding progression of renal failure in patients with HIVAN did not translate into improvement of survival of these patients on dialysis." />
  </sentences>
</list>